未经证实:有报告称索非布韦的肾功能恶化,但是没有不同直接作用抗病毒药物(DAA)对血清肌酐的比较数据。在这项回顾性队列分析中,我们检查了两种常用方案的治疗效果,sofosbuvir/ledipasvir(SOF/LDV)和glecaprevir/pibrentasvir(GLE/PIB),血清肌酐。
UNASSIGNED:我们纳入了2014年12月1日至2018年12月31日期间接受SOF/LDV(n=825)和GLE/PIB(n=116)治疗的所有患者。血清肌酐升高≥0.3mg/dL被认为具有临床意义。在未调整和调整的广义线性模型中测试两个治疗组之间从治疗前到治疗后的肌酐值的变化。并评估与肌酐变化相关的危险因素。此外,使用倾向评分将GLE/PIB治疗的患者与SOF/LDV治疗的患者进行1:2匹配,然后比较血清肌酐的变化。
UNASSIGNED:GLE/PIB组的平均基线肌酐较高。SOF/LDV组(1.39±1.86vs.0.91±0.24,P=0.007)。与基线相比时,SOF/LDV组治疗后第4周血清肌酐明显升高(0.97±0.4vs.0.91±0.24,P<0.001),但GLE/PIB组无明显变化(1.41±1.73vs.1.39±1.86,P=0.52)。总的来说,治疗后第4周和第24周血清肌酐无明显变化(P=0.6).在6%(46/825)的SOF/LDV和7%(8/116)的GLE/PIB(P=0.6)中可见血清肌酐的临床显着增加。未调整和调整的模型表明,从基线到治疗后第4周和第24周的肌酐变化与DAA组合的类型无关。
未经证实:用SOF/LDV和GLE/PIB方案治疗慢性丙型肝炎感染可能导致肌酐升高,6-7%的血清肌酐增加≥0.3mg/dL。肌酐的增加,然而,与DAA组合的类型无关。
UNASSIGNED: There are reports of worsening renal functions with sofosbuvir, but there are no comparative data of different direct-acting antivirals (DAAs) on serum creatinine. In this retrospective cohort analysis, we examined the treatment effect of two commonly used regimens, sofosbuvir/ledipasvir (SOF/LDV) and glecaprevir/pibrentasvir (GLE/PIB), on serum creatinine.
UNASSIGNED: We included all patients treated with SOF/LDV (n = 825) and GLE/PIB (n = 116) between December 1, 2014, and December 31, 2018. An increase of serum creatinine ≥0.3 mg/dL was considered clinically significant. The change of creatinine values from pretreatment to posttreatment between two treatment groups was tested in unadjusted and adjusted generalized linear model, and risk factors associated with creatinine change were assessed. In addition, GLE/PIB-treated patients were matched 1:2 to SOF/LDV-treated patients using propensity scores, and then serum creatinine changes were compared.
UNASSIGNED: The mean baseline creatinine was higher in the GLE/PIB group vs. SOF/LDV group (1.39 ± 1.86 vs. 0.91 ± 0.24, P = 0.007). When compared to baseline, serum creatinine at posttreatment week 4 was significantly higher in SOF/LDV group (0.97 ± 0.4 vs.0.91 ± 0.24, P < 0.001), but there was no significant change in the GLE/PIB group (1.41 ± 1.73 vs. 1.39 ± 1.86, P = 0.52). Overall, there was no significant change in serum creatinine between posttreatment week 4 and week 24 (P = 0.6). Clinically significant increase in serum creatinine was seen in 6% (46/825) of SOF/LDV and 7% (8/116) of GLE/PIB (P = 0.6). The unadjusted and adjusted models indicated that the changes in creatinine from baseline to posttreatment week 4 and week 24 were not associated with the type of DAA combination.
UNASSIGNED: Treatment of chronic hepatitis C infection with both SOF/LDV and GLE/PIB regimens may result in an increase of creatinine, and 6-7% will have an increase in serum creatinine of ≥0.3 mg/dL. The increase in creatinine, however, is unrelated to the type of DAA combination.